About Aditx Therapeutics
Aditx Therapeutics is a publicly listed company based in Loma Linda (United States) founded in 2017. Immune monitoring solutions are provided to the medical community. Aditx Therapeutics has raised $109.8 thousand across 4 funding rounds. The company has 26 employees. Aditx Therapeutics has completed 4 acquisitions, including AiPharma, Appili Therapeutics and Evofem Biosciences. Aditx Therapeutics offers products and services including Adimune, Pearsanta, Adivue, Appili, and Evofem. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases. Its legal entity is Aditxt, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Aditx Therapeutics was founded in 2017 and is based in Loma Linda, United States. Operations focus on the biotechnology sector, where a technology platform is commercialized to deliver personalized profiles of the immune system. Immune monitoring solutions are supplied to the medical community, with the AditxtScore product developed specifically for Covid-19 applications. The companys domain is aditxt.com, and key personnel include Amro Albanna.
- Headquarters Loma Linda, United States
- Employees 26
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website aditxt.com
- Social LinkedIn X Facebook YouTube
- Legal Name Aditxt, Inc.
- Annual Revenue$133.99 K (USD)-79.23as on Dec 31, 2024
- Net Profit-$34.45 M (USD)-6.38as on Dec 31, 2024
- EBITDA-$27.25 M (USD)-6.77as on Dec 31, 2024
- Total Equity Funding$109.8K (USD)
in 4 rounds
- Latest Funding Round$6M (USD), Post-IPO
Dec 2023
- Employee Count26
- Investments & AcquisitionsAiPharma
& 3 more
Products & Services of Aditx Therapeutics
Aditx Therapeutics offers a comprehensive portfolio of products and services, including Adimune, Pearsanta, Adivue, Appili, and Evofem.
Focuses on addressing autoimmunity issues through innovative health solutions.
Develops tools for early cancer detection in health diagnostics.
Targets neurological conditions with diagnostic innovations.
Plans programs for managing infectious disease challenges.
Focuses on reproductive health innovations and treatments.
Funding Insights of Aditx Therapeutics
Aditx Therapeutics has successfully raised a total of $109.8K across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $109,800
- Total Rounds 4
- Last Round Post-IPO — $6M
- First Round $109,800
(Dec 2018)
All 4 funding rounds of Aditx Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $6M | Post-IPO | – | – | – |
| Sep 2023 | $10M | Post-IPO | – | – | – |
| Jan 2021 | $6M | Post-IPO | – | – | – |
| Dec 2018 | $109,800 | Seed | – | – | – |
People of Aditx Therapeutics
21 people are tracked at Aditx Therapeutics (11 in leadership, 3 in board & advisors, 7 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Amro Albanna | Leadership | |
Corinne Pankovcin | Chief Commercialization Officer | Leadership |
Rowena Albanna | COO | Leadership |
Shahrokh Shabahang | Co-Founder, Chief Innovation Officer & Board Member | Leadership |
Thomas J. Farley | CFO | Leadership |
Sunny Uberoi | Chief Communications Officer | Leadership |
Jennifer Lee | Director, Human Resources | Leadership |
Christopher Porcelli | General Counsel, Chief People Officer And Corporate Secretary | Leadership |
Thomas Eaton | Senior Vice President - Corporate Finance And Investor Relations | Leadership |
Steve Varvel | Director Of Clinical Trials - Aditxtscore | Leadership |
Rodger Paxton | Vice President, Information Technology & Security Officer (remote) | Leadership |
Brian Brady | Board Member | Board & advisors |
Namvar Kiaie | Board Member | Board & advisors |
Jeffrey Runge | Board Member | Board & advisors |
Joachim-Friedrich Kapp | SVP, Clinical Development, Autoimmunity | Team |
Ge Chen | SVP, Preclinical Research & Discovery | Team |
Dolly Tyan | SVP, Clinical Development, Transplantation | Team |
Simon Peter Sansano | Operations And Compliance Manager | Team |
Rochelle Renkar | Pre-analytics And Phlebotomy Services Manager | Team |
Jazmin Reid | Client Services | Team |
1 more people are available in the full profile.
Complete people profiles for Aditx Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aditx Therapeutics
Aditx Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ADTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jun 2020
- Listed onNASDAQ: ADTX
- Listed entityAditxt, Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by Aditx Therapeutics
Aditx Therapeutics has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include AiPharma, Appili Therapeutics and Evofem Biosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Offers proteomics assays for physician support and therapeutic development. | igniteproteomics.com | 2024 | Mar 2026 | •••• | ||
Developer of drugs to treat infectious diseases | appilitherapeutics.com | Halifax, Canada | 2015 | Apr 2024 | •••• | |
Therapeutics for women's reproductive care are developed. | evofem.com | San Diego, United States | 2009 | Dec 2023 | •••• | |
Pharmaceutical drugs are manufactured by AiPharma in Dubai. | aipharmalab.com | Dubai, United Arab Emirates | 2020 | Dec 2021 | •••• |
Complete acquisition details for Aditx Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aditx Therapeutics
9 dated milestones of Aditx Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Aditx Therapeutics is founded.
- Funding First funding round of $110K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Aipharma.
- Acquisition Acquires AiPharma.
- Acquisition Acquires Evofem Biosciences.
- Funding Latest funding round, Post-IPO, of $6.0M.
- Acquisition Acquires Appili Therapeutics.
- Acquisition Acquires Ignite Proteomics.
Competitors of Aditx Therapeutics
Aditx Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Aditx Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aditx Therapeutics
The website of Aditx Therapeutics (aditxt.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▼ 45.2% vs previous month
Websites whose visitors overlap most with Aditx Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
 d18rn0p25nwr6d.cloudfront.net | d18rn0p25nwr6d.cloudfront.net | 100% | – | ||
quantisnow.com | quantisnow.com | 98% | #13,528,768 | – | |
| immutep.com | 39% | 8.9K | #2,562,349 | View details | |
westorg.org | westorg.org | 30% | #5,528,792 | – |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Aditx Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aditx Therapeutics
Complete news archive for Aditx Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aditx Therapeutics
Aditx Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Aditx Therapeutics is headquartered in Loma Linda, United States. It is registered at Loma Linda, California, United States.
Aditx Therapeutics is a funded company, having raised a total of $109.8K across 4 funding rounds to date. The company's 1st funding round was a Seed of $109.8K, raised on Dec 2018.
Aditx Therapeutics has 26 employees.
Annual revenue of Aditx Therapeutics is $133.99K as on Dec 31, 2024.
Aditx Therapeutics was founded in 2017 and is based in Loma Linda, United States. Operations focus on the biotechnology sector, where a technology platform is commercialized to deliver personalized profiles of the immune system. Immune monitoring solutions are supplied to the medical community, with the AditxtScore product developed specifically for Covid-19 applications. The companys domain is aditxt.com, and key personnel include Amro Albanna.
Aditx Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Aditx Therapeutics offers Adimune, Pearsanta, Adivue, Appili, and Evofem.
Yes, Aditx Therapeutics is publicly traded on NASDAQ under the ticker symbol ADTX.
Aditx Therapeutics has made 4 acquisitions, including AiPharma, Appili Therapeutics, and Evofem Biosciences.
Aditx Therapeutics operates through Aditxt, Inc..